Welcome to our dedicated page for IM Cannabis SEC filings (Ticker: IMCC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
IM Cannabis Corp. filings document a foreign private issuer reporting on Form 6-K, with disclosures centered on its medical cannabis operations in Israel and Germany, material agreements, capital structure and governance. Recent reports cover convertible note and warrant financings, common share conversion terms, registration-statement incorporation by reference, Nasdaq minimum bid price compliance, and executive officer changes.
IMCC regulatory filings also include shareholder-meeting notices, board and management matters, risk-factor and regulatory disclosures, and operating or financial-result updates. The filings describe how financing instruments, common shares, warrants, listing requirements and governance actions affect the company’s public-company reporting framework.
IM Cannabis Corp. completed a US$225,000 convertible note financing with an institutional investor on July 1, 2026. The note carries an 8% annual interest rate, rising to 14% upon an event of default, and is repayable only in common shares through conversion.
The conversion price is the lower of a fixed US$0.152 per share or 90% of the lowest daily volume-weighted average price over the 20 trading days before conversion, subject to a US$0.0303 floor. The company also issued a warrant to purchase up to 1,483,386 common shares at C$0.22 per share, exercisable immediately for five years.
IM Cannabis received net proceeds of US$202,500, which it intends to use for general corporate purposes. The note has a 4.99% beneficial ownership cap, and the company agreed to reserve sufficient shares and file a Form F-3 resale registration statement for the note and warrant shares within agreed timelines.
IM Cannabis Corp. has entered a non-binding letter of intent to sell its European-focused assets to Slil.com Holding Ltd., a private entity beneficially owned and controlled by CEO Oren Shuster. Slil would acquire IMC Holdings, which will primarily hold the Company’s European operations after a pre-closing reorganization.
In return, Slil is expected to assume approximately C$10,500,000 of debt, including C$7,500,000 in retained liabilities and C$3,000,000 in certain short-term liabilities, which the Company believes would significantly reduce its debt burden and improve working capital and cash flow. IMC would retain its core Israeli operations and focus on that market. The deal is a related party transaction under MI 61-101; a special independent committee and an external financial consultant have been engaged, and the Company intends to rely on “Financial Hardship” exemptions, with completion subject to a definitive agreement and other customary conditions.
IM Cannabis Corp. filed a resale registration statement on Form F-3 covering 17,276,931 common shares for selling shareholders. The registered shares arise from the conversion of three recent convertible promissory notes and the exercise of accompanying common share purchase warrants.
The notes have principal amounts of US$250,000, US$300,000 and US$225,000, with related conversion and warrant exercise rights into IMC common shares. The registration statement has been filed with the SEC but is not yet effective, and the company will not receive proceeds from any resale of these shares by the selling shareholders.
IM Cannabis Corp. registers up to 17,276,931 Common Shares for resale by a single selling shareholder pursuant to recent private placements and related convertible promissory notes and warrants.
The shares include Notes Shares issuable on conversion of multiple promissory notes and Warrants Shares exercisable under accompanying warrants. The company will not receive proceeds from resale but will receive cash if warrants are exercised. The offering is conditioned to occur "from time to time after the effective date."
IM Cannabis Corp. entered into a private placement with an institutional investor, issuing a US$225,000 convertible note and a warrant for up to 781,250 common shares. The company received net proceeds of US$202,500, which it plans to use for general corporate purposes.
The note carries 8% annual interest, rising to 14% on default, and is repayable only in common shares. The conversion price is the lower of a fixed US$0.288 per share or 90% of the lowest 20-day volume-weighted average price, subject to a US$0.0576 floor and a 4.99% beneficial ownership cap.
The warrant is exercisable immediately at C$0.40 per share for five years, until June 3, 2031. IM Cannabis agreed to reserve sufficient shares and file a Form F-3 resale registration statement for the note conversion shares and warrant shares within agreed timeframes.
IM Cannabis Corp. reported weaker first quarter 2026 results as it continues to face operational and liquidity pressures. For the three months ended March 31, 2026, revenue fell to $8.7 million from $12.5 million a year earlier, mainly due to shipment delays, product mix changes and reduced imports linked to cash constraints. Gross profit declined to $1.4 million, cutting gross margin to 16% from 28%. The company swung from a net profit of $0.2 million in Q1 2025 to a net loss of $2.5 million, or $0.38 per share
Cash decreased to $1.0 million and IM Cannabis reported a shareholders’ deficit of $5.1 million and negative working capital of $12.6 million, leading management to state there is significant doubt about its ability to continue as a going concern. Operations in Israel were negatively affected by ongoing regional conflict, which disrupted suppliers, imports, logistics, workforce availability and sales activity, pressuring gross profit.
To support liquidity, the company completed several convertible note financings in early 2026, issued related warrants, and converted portions of the notes into equity, increasing common shares outstanding to 6,223,323 at March 31, 2026. Additional convertible notes and warrants were issued in April and May 2026, and loans were obtained from a major shareholder and an affiliate. The interim condensed consolidated financial statements are unaudited and have not been reviewed by the external auditors.
IM Cannabis Corp. entered into a US$300,000 convertible note and warrant financing with an institutional investor, closing on May 7, 2026. Together with a prior US$250,000 note, recent similar financings total US$550,000 in gross proceeds, with net proceeds intended for general corporate purposes.
Both notes bear 8% annual interest, increasing to 14% upon default, and are repayable only in common shares at a price tied to either a fixed rate or 90% of the lowest 20-day VWAP, subject to floor prices. The deals include warrants for up to 1,400,681 common shares in total, exercisable for five years, and are subject to a 4.99% beneficial ownership cap and four‑month resale restrictions. IM Cannabis agreed to file Form F-3 resale registration statements to allow the investor to resell conversion and warrant shares.
IM Cannabis Corp. reported that Nasdaq has notified the company it is not in compliance with the exchange’s minimum bid price rule, which requires a closing bid of at least $1.00 per share.
IMC has 180 calendar days, until October 6, 2026, to regain compliance by maintaining a closing bid of at least $1.00 for ten consecutive business days. Its shares will continue trading on the Nasdaq Capital Market under the symbol IMCC during this grace period. If IMC fails to regain compliance, it may qualify for an additional 180-day period if it meets other listing standards; otherwise, its common shares could be subject to delisting. The company states that maintaining its Nasdaq listing is a priority and it will monitor its share price and consider available options to cure the deficiency.
IM Cannabis Corp. entered a note purchase agreement with an institutional investor, issuing a US$250,000 convertible note and a warrant for up to 272,861 common shares. The company expects net proceeds of US$225,000 for general corporate purposes.
The note bears 8.0% annual interest, rising to 14.0% upon an event of default, and is repayable only in shares. Conversion uses the lower of a fixed price of $0.339 or 90% of the lowest 20-day VWAP, subject to a $0.07 floor price and a 4.99% beneficial ownership cap. The warrant is immediately exercisable at CAD$0.47 per share until April 6, 2031, with trading restrictions for four months, and the company must file a resale registration statement on Form F-3 within 30 trading days of closing.